You are currently viewing our desktop site, do you want to download our app instead?
Moneyweb Android App Moneyweb iOS App Moneyweb Mobile Web App

NEW SENS search and JSE share prices

More about the app

Sinovac in talks about setting up SA vaccine production, partner says

‘A phase one where we will do bottling and labelling, so that we can get vaccines out to the people of Africa as soon as possible,’ he added.
Image: Bloomberg

China’s Sinovac Biotech is in talks about setting up a vaccine production facility in South Africa with its local partner, the chief executive of Numolux said on Friday.

Hilton Klein made the comments at the launch of the South African leg of a global Phase III trial of Sinovac’s Covid-19 vaccine in children and adolescents.

Moneyweb Insider INSIDERGOLD

Subscribe for full access to all our share and unit trust data tools, our award-winning articles, and support quality journalism in the process.

Choose an option:

R63 per month
R630 per year SAVE R126

You will be redirected to a checkout page.
To view all features and options, click here.

A monthly subscription is charged pro rata, based on the day of purchase. This is non-refundable and includes a R5 once-off sign-up fee.
A yearly subscription is refundable within 14 days of purchase and includes a 365-day membership.

Click here for more information.

“This clinical trial is a precursor to the establishment of a South African vaccine manufacturing facility partnered by Sinovac and Numolux Group that will cover the entire spectrum of vaccinations beyond just the Covid-19 response,” Klein told a news conference.

“We are in talks with Sinovac to set up a vaccine manufacturing facility. A phase one where we will do bottling and labelling so that we can get vaccines out to the people of Africa as soon as possible,” he added.

Sinovac did not immediately respond to a request for comment.

Sinovac and Numolux are enrolling 2,000 participants in the South African leg of their study evaluating the efficacy, immunogenicity and safety of the CoronaVac vaccine on children and adolescents aged 6 months to 17 years.

The global trial will also enrol participants in Chile, the Philippines, Malaysia and Kenya.

South Africa’s government is considering using the CoronaVac vaccine in its immunisation programme alongside shots developed by Pfizer-BioNTech and Johnson & Johnson which have been administered so far.

Drugs regulator SAHPRA in July gave conditional authorisation for use of Sinovac’s vaccine against Covid-19 for people aged between 18 and 59 years.

COMMENTS   0

You must be signed in to comment.

SIGN IN SIGN UP

LATEST CURRENCIES  

USD / ZAR
GBP / ZAR
EUR / ZAR
BTC / USD

Podcasts

INSIDER SUBSCRIPTIONS APP VIDEOS RADIO / LISTEN LIVE SHOP OFFERS WEBINARS NEWSLETTERS TRENDING PORTFOLIO TOOL CPD HUB

Follow us:

Search Articles:
Click a Company: